We investigated the molecular events involved in the long-lasting reduction of adipose mass by the selective CB1 antagonist, SR141716. Its effects were assessed at the transcriptional level both in white (WAT) and brown (BAT) adipose tissues in a diet-induced obesity model in mice. Our data clearly indicated that SR141716 reversed the phenotype of obese adipocytes at both macroscopic and genomic levels. First, oral treatment with SR141716 at 10 mg/kg/d for 40 days induced a robust reduction of obesity, as shown by the 50% decrease in adipose mass together with a major restoration of white adipocyte morphology similar to lean animals. Second, we found that the major alterations in gene expression levels induced by obesity in WAT and BAT were mostly reversed in SR141716-treated obese mice. Importantly, the transcriptional patterns of treated obese mice were similar to those obtained in the CB1 receptor knockout mice fed a high-fat regimen and which are resistant to obesity, supporting a CB1 receptor-mediated process. Functional analysis of these modulations indicated that the reduction of adipose mass by the molecule resulted from an enhanced lipolysis through the induction of enzymes of the β-oxidation and TCA cycle, increased energy expenditure, mainly through futile cycling (calcium and substrate), and a tight regulation of glucose homeostasis. These changes accompanied a significant cellular remodeling and contributed to a reduction of the obesity-related inflammatory status. In addition to a transient reduction of food consumption, increases of both fatty acid oxidation and energy expenditure induced by the molecule summate leading to a sustained weight loss. Altogether, these data strongly indicate that the endocannabinoid system has a major role in the regulation of energy metabolism.
The exact mechanism of the antiobesity effect of the molecule has not yet been elucidated. Indeed, the above-mentioned effect of SR141716 on food intake is transient, whereas the molecule was found to have a sustained effect on body weight loss. This suggests that the reduction in food intake may be the main initial cause of body weight loss but then relay mechanisms which remain to be identified, may account for the long-term antiobesity effect of SR141716.
The primary goal of this study was to identify genes regulated at the transcriptional level by SR141716 in adipose tissues of diet-induced-obese mice, a mouse model that closely resembles human obesity. We focused on WAT and BAT because 1) they showed major weight changes, which suggested that they were the main peripheral target tissues and 2) expression of CB1 receptors in these tissues is consistent with a potential peripheral effect of SR141716. Here, we reported the functional classification of genes that were modulated by long-term treatment with SR141716 in WAT and BAT, and we performed an immunohistochemical analysis of selected modulated proteins in WAT. In parallel, we compared the SR141716 transcriptional signature with the CB1 receptor knockout signature obtained in mice fed a high-fat diet. The identification of the metabolic pathways associated with these gene expression changes allowed us to outline the possible mechanisms through which the molecule could exert its sustained antiobesity effect.
MATERIALS AND METHODS

Animals and treatments
The present animal experiments complied with the relevant European and French laws and with the guiding principles for experimental procedures as set forth in the Declaration of Helsinki. In all experiments, mice were housed on a reverse light-dark cycle in a room with temperature and humidity control. They were fed either a high-fat diet (HFD) of 4.7 kcal/g energy density (TD 97366, Harlan, 49% fat, 18.5% protein, 33% carbohydrate) or a standard mouse diet (STD) containing 2.9 kcal/g (A04, UAR; 8% fat, 19% protein, 73% carbohydrate). Six-week old C57BL/6J male mice, from Iffa Credo (France) were fed ad libitum for 12 weeks with STD or HFD before treatment started. These mice were treated with either vehicle or SR141716 [Npiperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide] at 10 mg/kg orally in distilled water with 0.1% Tween 80 for 40 days. Their body weight was recorded weekly. Food intake was measured and energy intake relative to body weight was expressed as the ratio between energy intake expressed as kilocalories and the body weight × 100. In parallel, 9-week-old 129 C57 wild-type or CB1 receptor knockout (9) male mice were fed STD or STD/HFD for 11 wk, as described previously (9) , and their weight was recorded. After sacrifice, interscapular brown adipose tissue (BAT), lumbar white adipose tissue (WAT), and skeletal muscles (gastrocnemius and soleus) were isolated, weighed, and snap-frozen in liquid nitrogen. Plasma leptin levels were determined with radioimmunoassay kits (Linco Research kit). Twelve mice per group were used.
RNA and biotinylated probes preparation
Total RNA was isolated from BAT and WAT using the guanidium isothiocyanate method and purified by ultracentrifugation on a cesium chloride gradient. RNA preparation quality was assessed using the Agilent 2100 Bioanalyzer (data not shown). Each experimental point was equivalent to 12 mice, total RNA from 4 mice were pooled, and double-stranded cDNA was prepared from 5 µg of pooled total RNA using the Life Technologies superscript choice system and an oligo(dT)24 anchored T7 primer. Biotinylated RNA was synthesized using the T7 megascript system (Ambion, Austin, TX). After purification, labeled cRNAs were fragmented to 50-200 bases in length at 94°C for 35 min.
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Microarrays
Affymetrix mouse Mu74Av2 arrays (Santa Clara, CA) containing 12,000 genes and EST (Expressed Sequence Tags) were hybridized with biotinylated cRNA products (10 µg/chip) for 16 h at 45°C. After hybridization, arrays were washed, stained on the Affymetrix Fluidic Station 400, and then scanned using the Affymetrix, Hewlett-Packard scanner.
DNA chip data analysis
Low-level data analysis was performed using MAS 5.0 software (Affymetrix Inc.) by running absolute analyses on each array and comparative analyses between pairs of arrays hybridized with control and treated samples, respectively. All arrays were scaled to a mean gene expression intensity value of 300. Comparative analyses identify modulated genes and provide estimates of the expression intensity ratios for each gene between the pairs of hybridized arrays being compared. The ratios are expressed in base 2 logarithmic scale and called SLR (signal log ratios). Only genes whose expression modulated in 100% of the pairwise comparative analyses were considered significantly modulated. In addition, genes absent in both treated and control samples in more than 75% of comparisons were excluded. Cluster analysis was performed on SLR values.
Histology
Lumbar white fat from HFD mice treated or not with 10 mg/kg SR141716 for 40 days was fixed in formalin-alcohol for 48 h and paraffin-embedded. Three millimeter-sections were stained with hematoxylin and eosin and processed with routine immunohistological analysis technique. Sections were analyzed using a Leica DMLB microscope. The diameter of 100 cells in two different microscopic fields was determined. Nuclei were labeled using SYTOX Orange nucleic acid stain (Molecular Probes), according to the manufacturer's instructions.
Immunohistochemistry
When performing global gene expression analyses, a false positive might occur. In this context, specific experiments using real-time PCR or Western immunoblotting of the gene products need to be routinely performed to confirm gene modulations conclusively. Thus, here as a control, a few gene products were analyzed using an immunohistochemical approach and specific antibodies. Expression of α-actin, leptin, serca-1, and HSP47 proteins was analyzed using mouse monoclonal anti α-actin (1:100), anti-leptin (1:100), anti-serca-1 (1:20) antibodies and a rabbit polyclonal anti-HSP47 antibody (1:100) (Santa Cruz). Three micrometer-thick paraffinembedded sections or five micrometer-thick freeze sections were analyzed using the streptavidin-biotin method (Zymed Histomouse kit). Before mounting, sections were counterstained with Mayer's hematoxylin, and labeling was monitored through a high-power lens (×400). The primary antibody was omitted for the negative control.
Statistical analysis
The results are expressed as the mean ± SEM for each treatment group. Statistical analysis was performed using RS1 software. A treatment × time ANOVA (with repeated measures on the time Page 4 of 27 (page number not for citation purposes) factor) followed by Dunnett's tests was conducted on food intake and body weight. The other data were analyzed by one-way ANOVA followed by Dunnett's test.
RESULTS
SR141716 was previously shown to significantly reduce obesity in the diet-induced obesity (DIO) model (11) . To gain insight into the mechanisms leading to the antiobesity effect of the molecule and focus our study on its long-term effects, we ran a similar experiment with a longer duration of treatment and analyzed SR141716-specific gene expression modulations in adipose tissues. In addition, we compared these transcription profiles with that obtained in WAT and BAT from CB1 receptor knockout mice fed a high-fat diet for 11 weeks.
SR141716 reduced obesity in DIO mice
C57BL/6J mice were fed either a standard (STD) or a high-fat diet (HFD) for 12 wk beginning at 6 wk of age, then treated with SR141716 at 10 mg/kg/day per os for 40 days. At the beginning of the treatment with SR141716, HFD mice weighed 40.9 ± 0.7 g, while STD mice weighed 30.6 ± 0.5 g, the difference between the 2 groups was 33% (Fig. 1A) . In the HFD group, the body weight markedly changed following 1 wk treatment, that is, the difference between SR141716-treated and vehicle-treated animals reached -11.5% (P<0.01). Then the body weight progressively declined in the SR141716-treated mice, while it remained constant in the vehicletreated group. At the end of the experiment, SR141716-treated HFD mice weighed 17.9% less (-10.3 g, P<0.01) than vehicle-treated HFD mice. In the STD group, drug-treated animal weights were not significantly modified. Again, the variation of body weight was the most important during the first week of treatment (-3.5%). At the end of the experiment, drug-treated animals exhibited a -3.3% weight difference (-1.0 g) compared with vehicle-treated STD mice. These body weight changes induced by SR141716 were highly reproducible and similar to those described previously (11) . Interestingly, compared with SR141716-STD mice, the body weight change in SR141716-HFD mice was in the same range as that obtained in CB1 receptor knockout mice that had been fed or not an obesity-prone regimen for 11 wk and that were described as resistant to obesity (9) (Fig. 1, insert) . This supports the hypothesis that the effects of the molecule on body weight were CB1 receptor-mediated.
Lumbar WAT and, to a lesser extent, BAT adipose tissue appeared to be the primary peripheral targets of the drug effect (Fig. 1B) . When tissue weights were expressed relative to total body weight, lumbar WAT and BAT were 64% and 46% less in SR141716-treated HFD animals compared with vehicle-treated animals at day 40 (P<0.01). In the STD group, we observed that SR141716 also reduced the relative lumbar WAT and BAT weights by 27% (P<0.01) and 6%, respectively. By contrast, in both groups, muscle weights (soleus and gastrocnemius) were not affected. Thus the changes in fat and lean contents in SR141716-treated HFD mice improved the body composition profile of these mice to that seen with lean animals.
The energy intake relative to body weight was more elevated in HFD mice than STD mice (Fig.  1C) . In the HFD group, SR141716-treated animals showed lower energy intake (-21%, P<0.01) than controls during the first week of treatment. By contrast, it was similar during the second week, and then slightly higher. The difference in relative food intake peaked at +21.7% (P<0.01) at the end of the third week of treatment and was +15.7 at day 40 (P<0.01). In the STD group, a similar variation within a narrower range was observed during the first week, and then both groups showed identical relative energy intake. Thus, the difference in body weight in the HFD group during the first week likely originated from a difference in food intake, while from the second week until the end of the treatment, the food intake could not account for the difference in body weight.
SR141716 reversed the obese adipocyte phenotype
White adipocytes in vehicle-treated HFD mice were large and exhibited heterogeneous sizes while adipocytes in SR141716-treated animals were significantly smaller than those in vehicletreated animals. The difference in the mean cell diameter was −57%, which resulted in an estimated difference in storage volume close to 90% (Fig. 2) . The mean cell diameter of SR141716-treated HFD white adipocytes was slightly smaller (around 10%) than STD white adipocytes. As an approach to cell density, we analyzed nucleus labeling in WAT on the same microscopic field, and found fewer nuclei in vehicle-treated HFD mice compared with STD mice: 23 vs. 46, respectively (Fig. 3) . By contrast, 67 nuclei were counted on the same field in SR141716-treated HFD mice. The elevated number of nuclei in SR141716-treated HFD WAT compared with STD WAT would reflect the prior obese status of these mice with adipocyte hyperplasia, suggesting that the body weight change was not the result of adipocyte apoptosis but rather of a dramatic depletion of the adipocyte's fat content.
The transcriptional signatures of obesity and SR141716 in obese mice were opposite
We used the DNA chip technology to compare the transcriptional profiles of diet-induced obese and nonobese mice treated or not with SR141716 in WAT and BAT. The "HFD signature" represented gene modulations induced by the high-fat regimen and was obtained by comparing the transcriptional profiles of mice fed HFD with those of mice fed STD. We observed that the response to the high-fat diet was associated with a substantial alteration in gene expression levels in WAT (Fig. 4A ) and BAT (Fig. 4B ). Expression patterns obtained in C57BL/6J and 129 C57 strains were similar, indicating that diet-induced obesity produced specific gene modulations independently of the mouse genetic background. As expected, gene modulations observed are consistent with those reported previously (12) (13) (14) . These included the induction of genes encoding cytoskeletal and extracellular matrix proteins and the repression of genes encoding mitochondrial enzymes or genes associated with adipocyte differentiation.
The transcriptional effect of SR141716 in obese animals was determined by comparing gene expression in SR141716-treated HFD mice with gene expression in vehicle-treated HFD mice, that is, SR141716 signature in HFD mice. Remarkably, most gene modulations induced by SR141716 in obese mice were in the opposite direction of those found in the HFD signature (Fig.  4A, B) . Almost no effect of SR141716 was observed in STD mice (Fig. 4A, B) . In parallel, we determined the CB1 receptor knockout signature in HFD mice (obtained by comparing gene expression in CB1 receptor knockout HFD mice and CB1 receptor wild-type HFD mice). Interestingly, the SR141716 signature in HFD mice and the CB1 receptor knockout signature in HFD mice showed very similar patterns supporting that SR141716-induced gene modulations resulted from a CB1 receptor-mediated process (Fig. 4A, B) .
Page 6 of 27 (page number not for citation purposes)
SR141716 enhanced lipolysis and energy expenditure in WAT of obese mice
The reduction in body weight induced by the drug was accompanied by specific gene modulations in WAT (Fig. 4A) . One can distinguish two groups: 1) modulations that would contribute to reducing fat storage; this group included genes that directly or indirectly regulate energy expenditure (lipid and glucose metabolism, calcium and substrate cycling, amino acid catabolism), and 2) modulations that were thought to occur as a consequence of the reduction in adipose mass, they included genes encoding specific adipocyte proteins or genes controlling cell morphology or inflammatory responses (Table 1) . Altogether, these modulations supported that SR141716 reversed the diet-induced obesity phenotype.
Lipolysis-β oxidation
SR141716 affected lipid metabolism as shown by the induced expression of numerous enzymes that play a role at each step of this pathway. SR141716 enhanced carnitine acetyltransferase (CAT) and carnitine palmityltransferase II (CPT2) expression. These enzymes transport acyl CoA esters into mitochondria and catalyze the reversible transfer of short-chain acyl groups between carnitine and CoA, which is required for both the β-oxidation pathway and the TCA cycle. The enoyl CoA hydratase, (or crotonase), which catalyzes the second step of β-oxidation of fatty acids, was induced. SR141716 was also found to increase the expression of three enzymes of the TCA cycle: fumarase, aconitase and oxoglutarate dehydrogenase. One component of the respiratory chain, that is, cytochrome c oxidase subunit VIa, which is a subunit of the complex IV was induced. Finally, the adenine nucleotide carrier (ANT), which is a carrier protein that exports ATP from mitochondria in exchange for ADP, was also increased. This is summarized in the schematic diagram shown in Fig. 8 . The coordinated induction of all of these genes acting at different levels of the fatty acid catabolism pathway strongly suggested that treatment with SR141716 favored lipolysis and thereby reduced fat storage in WAT. Activation of a redox pathway is often associated with the induction of β-oxidation and oxidative phosphorylation, as this leads to increased reactive oxygen species (ROS) production. Consistent with this observation, two antioxidant enzymes were induced by SR141716, that is, glutathione peroxidase 3, (GPX3) and flavin-containing monooxygenase (FMO1).
Interestingly, together with the modulation of lipolysis effectors, critical regulators of this pathway were also affected. For instance, SR141716 induced β 3-adrenergic and growth hormone (GH) receptors, whose activation stimulates lipolysis. In addition, SR141716 repressed the expression of catechol-0-methyltransferase (COMT), which is a methyltransferase involved in the degradation of catecholamines that are hormones with pronounced lipolytic action. The reduced expression of this enzyme along with the induction of these two receptors would likely contribute to favor the breakdown of triglycerides.
Besides the reduction in fatty acid energy storage, we observed the induction of creatine kinase (CK), which may generate an alternative energy storage system by producing phosphocreatine.
Increased energy expenditure
With the induction of four genes encoding calcium binding proteins, a treatment with SR141716 may generate a futile calcium cycling. They were Serca1, a sarcoplasmic reticulum Ca 1, which pumps calcium ions from the cytoplasm into the sarcoplasmic reticulum; Ryanodine receptor 1 (RyR1), a calcium release channel located at the membrane of the sarcoplasmic reticulum, which transfers calcium in the opposite direction, from the reticulum to the cytoplasm; and two calcium-binding proteins: parvalbumin and calsequestrin 1 (CASQ1), which are located in the cytosol and the reticulum lumen, respectively (Fig. 8) . The induction of Serca1 expression by SR141716 in obese mice was confirmed at the protein level by immunohistochemical analysis (Fig. 5) . Glycogen phosphorylase (GP) and glycogen synthase (GS), which were induced by SR141716 in WAT of obese mice, may generate a substrate cycling. Complementary activities of these two enzymes regulate cellular glycogen concentrations. GS is a rate-determining enzyme for glycogen synthesis and the immediate precursor is uridine diphosphate glucose (UDP-glucose). The UTP pool is generated by the activation of uridine kinase, which is induced by SR141716. Conversely, GP facilitates the breakdown of glycogen and produces glucose-1-phosphate, which in turn is converted to glucose-6-phosphate that can enter glycolysis. If glycogen synthesis and phosphorolysis were simultaneously active in a cell, there would be a "futile cycle." SR141716 increased the expression of three enzymes involved in amino acid degradation. They were cysteine dioxygenase (CDO), which is the initial and rate-limiting enzyme involved in the oxidative degradation of cysteine, methylcrotonoyl-CoA carboxylase, and methylmalonyl CoA mutase that are two enzymes of the valine, leucine, and isoleucine degradation pathway. Amino acid catabolism produces intermediates that can enter the TCA cycle. Protein degradation, ion, and substrate cycling create the possibility of futile cycles that are known to contribute to energy expenditure: indeed the demand for ATP required to sustain futile cycles drives fuel oxidation (15, 16) . The generation of futile cycles is consistent with the SR141716-induced reduction of energy storage in fat.
Glucose metabolism
SR141716 enhanced the gene expression of critical regulators of glucose metabolism. Four out of eight glycolytic enzymes were induced by SR141716. They include phosphofructokinase (PFK), glyceraldehyde 3 phosphate dehydrogenase (GAPDH), phosphoglycerate mutase (PGM), and β enolase (Fig. 8) . The latest step of this pathway is the overall conversion of pyruvate to acetyl-CoA and CO 2, which is catalyzed by the pyruvate dehydrogenase complex. This complex consisted of three enzymatic components and one enzyme of this complex─pyruvate dehydrogenase─was induced by SR141716. Finally, consistent with the activation of glucose metabolism, phosphoenolpyruvate carboxykinase (PEPCK), which catalyzes the limiting step in gluconeogenesis and the insulin-responsive glucose transporter, GLUT4, were induced. Increased glucose entry via transporters such as GLUT4 is known to contribute to enhance glycolysis. Altogether, these modulations may account for the SR141716-induced correction of insulin resistance.
Cytoskeleton organization
As a consequence of the reduction of fat storage, remarkable changes were observed in genes encoding cytoskeletal and extracellular matrix proteins. On the one hand, cytoskeleton structural proteins such as α actin, α actinin 3, myozenin, two actin binding proteins, cypher/LDB3, a cytoskeletal adaptor protein, the myosin heavy polypeptide 4 (MYH4), the slow myosin heavychain-β and the myosin light-chain 2, which are motor proteins, were induced by SR141716. The induction of α actin expression by SR141716 in obese mice was also confirmed at the protein level by immunohistochemistry (Fig. 6A) . Troponin T and troponin C, which regulate actin and myosin interactions, were also induced. Conversely, γ actin, involved in the establishment and maintenance of cellular morphology and cytoarchitecture, and α-tubulin, which polymerizes to form microtubules, were repressed by the drug. One member of the β-thymosin family, thymosin β 4 (Tβ4), which is an actin monomer sequestering protein involved in cell surface dynamics was also reduced. Together with the modulation of structural cytoskeleton proteins, we also observed that SR141716 decreased the expression of extracellular matrix regulators, that is, the matrix metalloproteinase 3, the macrophage metalloelastase, cathepsin S, and Hsp47, which is a procollagen-specific chaperone that regulates collagen biosynthesis. The decrease in Hsp47 expression by SR141716 in obese mice was confirmed at the protein level (Fig. 6B ). All these gene expression changes were indicative of a remodeling of adipocytes and supporting infrastructures. Such a remodeling is expected to be associated with the dramatic decrease in fat storage in WAT induced by the drug.
Adipocyte specific proteins, secreted proteins and inflammation
White adipose tissue is recognized as a secretory organ (17) . Together with the modulations of genes regulating energy metabolism, SR141716 also modulated the gene expression of adipocyte-secreted hormones and adipocyte specific proteins. Leptin, whose gene expression is induced in obese animals, was reduced by SR141716. This hormone contributes to the regulation of energy metabolism and feeding behavior (18) . Its down-regulation was also observed at the protein level via immunohistochemical analysis and plasma measurement (Fig. 7) . Plasma leptin levels were lowered by -53% in the HFD group treated by SR141716 compared with vehicletreated animals (P<0.05). No significant modulation was obtained in the STD group. The decreased adiposity was thus accompanied by a proportional fall in plasma leptin levels, which is in agreement with the known correlation of leptin with body fat mass in rodents and humans. The mouse adipose differentiation-related protein, ADRP, or adipophilin, is a lipid dropletassociated protein that is expressed early during adipose differentiation (19) . Its reduced expression by SR141716 is consistent with the diminution of fat storage in WAT. By contrast, SR141716 induced the expression of adipsin, adiponectin, resistin, and spot14. Adipsin is a serine protease that plays an important role in activation of the alternative complement pathway, and its expression was shown to be repressed in obesity and induced during adipogenesis (12, 20) . Adiponectin (ACRP30 or adipoQ) is exclusively secreted by differentiated adipocytes and is thought to contribute to the control of energy homeostasis. The SR141716-induction of adiponectin mRNA in WAT obtained here is in agreement with previous work from Bensaid and colleagues who reported that adiponectin mRNA expression was increased in rat adipose tissue and mouse 3T3 adipocytes upon treatment with SR141716 (21). Resistin is an adipocyte-secreted molecule induced during adipocyte differentiation. Functional studies suggest that resistin reduces insulin action in mice (22) . Spot 14 is a nuclear protein mainly expressed in tissues that synthesize triglycerides. Its induction has been observed during adipogenesis (12) . Altogether, these changes induced by SR141716, which are all observed at different stages of adipogenesis, may be indicative of the reestablishment of the adipocyte differentiation program, which has been stopped by adiposity.
Obesity is known to be associated with inflammatory conditions (23) . Expression of genes such as lipocortin 1, LPS binding protein (LBP), and lysozyme M, which mediate inflammatory responses and have already been reported to be up-regulated in diet-induced obesity (13) was
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reduced by SR141716. In addition, other inflammatory markers, acute-phase genes or gene products expressed in macrophages such as MIP1γ, plasminogen activator inhibitor -1 (PAI-1), serum amyloid A3, and mac-2 antigen were also reduced. The down-regulation of these genes suggested that SR141716 also limited inflammatory conditions associated with obesity.
SR141716 favored thermogenesis in BAT
Compared with white fat cells, brown fat cells have virtually the same enzymatic machinery. Lipids are accumulated to a lesser extent, and they serve mainly as a source of fatty acid to be oxidized in mitochondria rather than acting as an energy storage depot. Consistent with the changes observed in WAT, we observed that SR141716 affected the expression of genes involved in energy storage and expenditure, genes encoding specific adipocyte secreted proteins and also genes involved in the regulation of mitochondrial functions in BAT (Fig. 4B, Table 2 ).
The fatty acid CoA ligase, which catalyzes the formation of fatty acyl-CoA that serves as substrates for β-oxidation, was induced in BAT. Mitochondrial activities were specially affected with the induction of three members of the oxidative phosphorylation pathway: NADH ubiquinone oxidoreductase, ubiquinol cytochrome c reductase and F1F0-ATP synthase. In line with the activation of mitochondrial activities, SR141716 also induced the expression of chaperonine 10 (HSP10), which regulates mitochondrial biogenesis. In addition, SR141716 enhanced the expression of type II deiodinase, DIOII, and type III adenylyl cyclase. DIOII catalyzes the production of 3,3′,5-triiodothyronine (T3) that activates thermogenesis in BAT, and the adenylyl cyclase increases intracellular cAMP levels, which activates protein kinase A and subsequently leads to the activation of hormone-sensitive lipase. These modulations would contribute to limit fat energy storage and tend to favor energy dissipation through mitochondrial heat production in BAT.
As observed in WAT, a redox pathway was also activated in BAT with the induction of the antioxidant metallothionein-1, carbonic anhydrase 3, FMO1, and GPX3. The latter two enzymes were also induced by the drug in WAT. Noticeably, the induction of metallothionein expression in BAT was reported to be indicative of activation of thermogenesis (24) . In addition, as evidenced in WAT, SR141716 also affected the expression of genes involved in regulation of the cytoskeleton organization and extracellular basement structure in BAT. For instance, genes such as tubulin, type I and III procollagens and procollagen C proteinase enhancer protein are all reduced by the drug. Secreted proteins repressed by SR141716 in BAT included leptin (as observed in WAT) and SPARC, a matricellular protein, which mediates cell-matrix interactions and may influence adipocyte hyperplasia (25) . Both are up-regulated in obesity. Finally, two groups of genes involved in immune responses or lipid transport were significantly reduced by SR141716 in BAT.
DISCUSSION
In contrast to the rapid return of food intake to the baseline level, the body weight of SR141716-treated animals constantly declined relative to that of vehicle-treated animals throughout the entire treatment period. The results presented here shed some light on the mechanisms involved in the long-term antiobesity effect of SR141716 and showed that the molecule reversed the phenotype of obese adipocytes. Comparisons between treated obese mice and nontreated obese animals revealed remarkable differences at both macroscopic and genomic levels. First, the molecule given orally at 10 mg/kg/day SR141716 for 40 days reduced body weight by 17.9%. This effect is the result of a strong decrease in WAT and BAT weights, which were both reduced by more than 50% following treatment. The size of white adipocytes was reduced by more than a half, resulting in a deep reduction of fat storage volume by more than 90%. Second, the analysis of gene expression patterns at the end of the treatment indicated that the above-mentioned modifications of body weight and fat storage were accompanied with changes in gene expression profiles in WAT and BAT. Precisely, the SR141716 transcriptional signature and the obesity signature are opposite. Different metabolic pathways were affected by the drug, as summarized in Fig. 8 . The reduction in fat storage induced by the drug may result from induction of lipolysis together with increased energy expenditure, mainly through the generation of futile cycles and increased glycolysis. A direct consequence of the fat storage reduction was the modulation of adipocyte genes involved in adipocyte morphology control and reduced inflammatory status. Among the genes that were modulated by SR141716, we observed changes in the expression of molecular markers that generally distinguish mature adipocytes from preadipocytes (20) . These include numerous genes involved in lipolysis, glucose metabolism, and all the genes that are grouped in the fatty acid and glucose metabolism control category. When analyzing changes in gene expression in obesity in different mouse models, Nadler and coworkers reported that the expression of genes normally associated with adipocyte differentiation were down-regulated in obesity (12) . Their observations led to the hypothesis that some degree of dedifferentiation has taken place in the adipose tissue. This question has not yet been fully addressed, but Zhou and colleagues suggested that the alteration of the adipocyte phenotype may have a sustained effect on fat storage reduction, and this would thereby represent a strategy for the long-term treatment of obesity (26) . The modulations that we documented indicate that SR141716 reversed the dietinduced alteration of the adipocyte phenotype, suggesting that the molecule may affect a differentiation program that has been altered by obesity.
SR141716 was previously shown to have no effect in CB1 receptor knockout mice, which are resistant to diet-induced obesity (9) . Importantly, the gene modulations obtained in CB1 receptor knockout mice fed a high-fat diet were similar to those observed in obese mice treated with the CB1 antagonist SR141716. This supports our hypothesis that the SR141716-dependent gene modulations resulted from a CB1 receptor-mediated process. Given this, important questions are raised.
Are these modulations associated with a central or peripheral effect of the molecule? The hyperphagic actions of cannabinoids were first considered as being mediated exclusively by CB1 receptors located in the brain. However, recent evidence has been provided that peripheral mechanisms may also be involved. CB1 receptors are also expressed on sensory nerve terminals innervating the gastrointestinal tract, which are known to be involved in mediating satiety signals that originate in the gut (27) . In addition, food deprivation was shown to produce a sevenfold increase in anandamide content in the small intestine but not in the brain or stomach. Peripheral but not central administration of SR141716 reduced food intake (28), although these results are highly controversial. Cota and colleagues recently demonstrated that activation of CB1 receptors using a specific CB1 agonist enhanced lipogenesis in primary adipocyte cultures (29) . In line with this, Bensaid and coworkers showed that rat adipose tissue and mouse 3T3 adipocytes expressed CB1 receptors and produced adiponectin upon SR141716 treatment (21) . Thus,
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adipose tissue itself could be the site of action of SR141716 with regard to a potential peripheral effect of the molecule.
How can we explain that the sustained effect of the molecule on body weight loss is restricted to obese animals and does not affect lean ones? There is still no clear explanation. Obesity is now recognized as a pathological state with numerous deregulated pathways. Considering the cannabinoid system, on the one hand CB1 receptors were reported to have increased expression in obesity (21) . On the other hand, indirect data argued for an exaggerated endocannabinoid formation in obesity that may contribute to a hyperactive endocannabinoid system (30) . The intrinsic efficacy of SR141716 may thus be due to antagonism of an endogenous tone of the cannabinoid system. In addition, CB1 receptors may be auto-activated, as the receptor was described as being spontaneously precoupled to G proteins in the cell membrane (31) . This form can be blocked by SR141716 due to the inverse agonism activity of the molecule (32) . In this context, one can assume that SR141716 affected only obese animals because the molecule, through the cannabinoid system, may impact a pathway that is activated only in obesity.
What is the molecular link between CB1 activation and the here-described gene modulations? Gene expression profiling is a well-established approach for analyzing biological processes globally. However, as a result, it does not allow one to distinguish primary and secondary targets. Noticeably, we show evidence here that the molecule-induced gene expression patterns were strictly in the opposite direction of those induced by the high-fat regimen. This suggests that treatment with SR141716 induced coordinated events that jointly led to the normalization of transcriptional events involved in obesity. In addition, we found that the SR141716-induced modulations were similar to those obtained when comparing gene expression in CB1 receptor knockout with CB1 receptor wild-type mice fed a high-fat diet. Altogether, these data support the view that SR141716 would act through the CB1 receptor and target upstream pathways along the cascade, regulating energy expenditure and food intake. Studies are currently under way to identify primary targets involved in regulation of energy balance by the cannabinoid system.
Shedding new light on the potential role of the cannabinoid system in the regulation of energy expenditure and lipogenesis/lipolysis, the data reported here open new avenues to analyze the actual role of the cannabinoid system in both physiological and pathological, that is, obesity, conditions. A step further would be, for instance, to assess the effect of CB1 receptor stimulation by agonists on the expression of the genes reported here to be up-or down-regulated. Furthermore, the impact of other effectors of lipogenesis and lipolysis on the expression of endocannabinoid biosynthesizing and metabolizing enzymes also needs to be investigated. male mice were first fed either STD or HFD for 12 wk beginning at 6 wk of age, then treated for 40 days with SR141716 at 10 mg/kg/day per os. During treatment, animals were maintained with their respective diet, and their weight was recorded regularly. B) After sacrifice, brown adipose tissue (BAT), white adipose tissue (WAT), and skeletal muscles (gastrocnemius and soleus) were isolated and weighed. For representation, organ weights were corrected for differences in total body weight. C) Relative food intake per week is expressed as energy intake in kilocalories divided by the body weight × 100. Statistical analysis compared the drug-treated groups to their respective vehicle-treated controls (*P < 0.05, **P < 0.01). Insert: Body weights in C57BL/6J mice fed either STD and HFD after a 40-day treatment with SR141716 at 10 mg/kg/day postoperatively and in CB1 receptor knockout 129 C57 mice fed a standard (STD) or an obesity-prone regimen (HFD) at 20 wk of age, after an 11-week regimen (9) . 
